Glenmark, Torrent in pact for diabetes drug

Glenmark Pharmaceuticals and Torrent Pharmaceuticals have entered into a non-exclusive, sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor Remogliflozin Etabonate (Remogliflozin) in India. Under the terms of the agreement, Glenmark would receive an upfront payment, licence fee and royalties for the non-exclusive, sub-licence rights from Torrent.

Glenmark will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark ‘Zucator’ in India, Glenmark said in a statement.

Source: Read Full Article